<DOC>
	<DOCNO>NCT01319877</DOCNO>
	<brief_summary>This observational study evaluate safety efficacy Bevacizumab combination 5-Fluorouracil base chemotherapy first-line second-line therapy Chinese participant metastatic colorectal cancer . Data collect participant 3 year .</brief_summary>
	<brief_title>An Observational Study Bevacizumab Combination With 5-FU-Based Chemotherapy Chinese Participants With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Adult Chinese participant , &gt; /= 18 year age Histologically confirm previously untreated metastatic colorectal cancer Initiated treatment Bevacizumab ( combination 5FU base chemotherapy ) accord locally approve Bevacizumab China package insert Documented participant medical record Recent history serious hemorrhage hemoptysis &gt; /= 1/2 teaspoon red blood Proteinuria baseline ( &gt; /=2 gram / 24 hour ) Major surgical procedure within 28 day prior study treatment start , fully heal wound Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>